Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Sarcomas are rare cancers with limited treatment options.
• Epigenetic therapies, including histone deacetylase inhibitors (HDACI) and DNA-methyltransferase inhibitors (DNA-MI), show promise but require predictive biomarkers.
• The combination of HDACI and DNA-MI may offer synergistic therapeutic effects.

Purpose of the Study:

• To investigate the therapeutic potential of combining HDACI and DNA-MI in a large panel of sarcoma cell lines.
• To identify predictive biomarkers for response to combination epigenetic therapy.
• To elucidate the underlying epigenetic mechanisms driving synergistic drug responses.

Main Methods:

• Treatment of diverse sarcoma cell lines with five HDACIs and decitabine (DNA-MI), alone and in combination.
• In vitro and in vivo validation of a two-gene signature (CUGBP2 and RHOJ) associated with synergistic drug response.
• Analysis of chromatin modification and gene expression, including CDKN1A (p21), to understand epigenetic mechanisms.

Main Results:

• Individual HDACI efficacy was consistent across cell lines, while decitabine monotherapy showed minimal effect.
• Combination HDACI/DNA-MI therapy demonstrated preferential synergism in specific sarcoma cell lines.
• A predictive gene signature (high CUGBP2; low RHOJ) was identified and validated.
• Epigenetic synergism was linked to baseline chromatin structure and p21 upregulation in sensitive cell lines.
• Identified epigenetic patterns were also present in high-grade primary sarcomas.

Conclusions:

• Combined HDACI/DNA-MI therapy can induce synergistic effects in specific sarcoma subtypes.
• The CUGBP2/RHOJ gene signature serves as a predictive biomarker for response to this combination therapy.
• Baseline chromatin structure influences epigenetic drug response, offering mechanistic insight into therapy effectiveness.
• Findings support the clinical investigation of combined epigenetic therapies guided by predictive gene signatures in sarcoma patients.